Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

about

Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.

P2860

Q37671216-EF0C2111-79BE-44E6-95AE-ED3F53595459 Q55283579-6596320C-03B8-407F-812F-514AA036A1FD

P2860

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

Item

http://www.wikidata.org/entity/Q26775363

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

@ast

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

@en

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

@nl

type

Item

label

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

@ast

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

@en

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

@nl

prefLabel

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

@ast

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

@en

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

@nl

P1476

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

@en

P2093

Fatemeh Davami

http://www.w3.org/2001/XMLSchema#string

Fatemeh Naddafi

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting CD19 in B-cell lymphoma: emerging role of SAR3419

Bispecific T-cell engaging antibodies for cancer therapy

B cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding.

Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19.

Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.

P304

143-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26629482

http://www.w3.org/2001/XMLSchema#string

P921

antibody

P932

4644525

http://www.w3.org/2001/XMLSchema#string

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

about

P2860

P2860

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P921

P932

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P921

P932